Skip to content
10-Q

Quarterly Report

Immunoclin Corp

0001517126-14-000393

← back to feed
Filed
Dec 22, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2015 · Dec 22, 2014 28.83M sh
Capex Q3 2015 · Oct 31, 2014 $6.35K
Capex Q3 2015 · Oct 31, 2013 $1.32K
Operating Cash Flow Q3 2015 · Oct 31, 2014 −$180.63K
Operating Cash Flow Q3 2015 · Oct 31, 2013 −$82.42K
Stockholders Equity Q3 2015 · Oct 31, 2014 $17.55M
Stockholders Equity Q3 2015 · Jan 31, 2014 $19.8M
Current Liabilities Q3 2015 · Oct 31, 2014 $2.84M
Current Liabilities Q3 2015 · Jan 31, 2014 $725.47K
Current Assets Q3 2015 · Oct 31, 2014 $244.99K
Current Assets Q3 2015 · Jan 31, 2014 $74.01K
Total Assets Q3 2015 · Oct 31, 2014 $20.39M
Total Assets Q3 2015 · Jan 31, 2014 $20.53M
Sga Expense Q3 2015 · Oct 31, 2014 $110.09K
Sga Expense Q3 2015 · Oct 31, 2014 $310.09K
Sga Expense Q3 2015 · Oct 31, 2013 $56.05K
Sga Expense Q3 2015 · Oct 31, 2013 $104.79K
Rd Expense Q3 2015 · Oct 31, 2014 $27.61K
Rd Expense Q3 2015 · Oct 31, 2013 $72.2K
Rd Expense Q3 2015 · Oct 31, 2013 $97.52K
Net Income Q3 2015 · Oct 31, 2014 −$6.12M
Net Income Q3 2015 · Oct 31, 2014 −$7.91M
Net Income Q3 2015 · Oct 31, 2013 −$178.26K
Net Income Q3 2015 · Oct 31, 2013 −$440.36K
Operating Income Q3 2015 · Oct 31, 2014 −$6.35M
Operating Income Q3 2015 · Oct 31, 2014 −$8.15M
Operating Income Q3 2015 · Oct 31, 2013 −$179.89K
Operating Income Q3 2015 · Oct 31, 2013 −$441.99K
Revenue Q3 2015 · Oct 31, 2014 $5K
Revenue Q3 2015 · Oct 31, 2014 $5K